Companies in fourth cohort developing products ranging from software to therapeutic platforms; applications for fifth cohort, in partnership with MLA48, open until May 27, 2016 TORONTO (May 9, 2016) —…
Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017 HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device…
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein.
The article explores the role life sciences assets, financing and talented management–the three Ms–must play in revitalizing Canada’s biotechnology sector:
At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage.
You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the Canadian venture capital industry Finding suitable investment for early-stage technologies became incredibly challenging. Facing a dearth of opportunity, talented management sailed for other harbors.
It’s satisfying that on the eve of the 2014 BIO Convention, some indicators suggest to me that we are witnessing a rebound. But to accelerate our pace while holding this bearing, Canada needs to address certain strategic elements.
At MaRS Innovation, we call them the three Ms: merchandize, management and money.
Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery
BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.
Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.